Formulation Development Outsourcing Market Synopsis

Formulation Development Outsourcing Market Size was valued at USD 26.8 Billion in 2023, and is Projected to Reach USD 58.6 Billion by 2032, Growing at a CAGR of 9.1% From 2024-2032.

Outsourcing of formulation development means that those jobs are handed over to third parties, in this case service providers, to formulate and enhance pharmaceutical formulations on behalf of the contracting party. To be specific, Dr. Poc Wisniak specified that the process involves developing the drug product and identifying suitable excipients as well as identifying the manufacturing method to achieve safety, efficacy, and stability. Vendor resources introduced better technology, domain know-how, or improved, legal comprehension that can help in getting new solutions to marketplace quicker and at lower cost. Firms choose to outsource as they gain the ability to focus on business processes that are unique to their organization, capture the best talent from across the world, and utilize existing service provider expertise in manage external regulatory frameworks and ensure product launch success.

• The formulation development outsourcing market has continuously expanded over the past few years with the increased pressure on the complexity of drug development, continuously rising research and development costs, as well as the requirement of specialty in the drug production. This trend has seen Pharm and Biosciences outsourcing partners come in to supplement their product portfolios in an attempt to quicken their presence in the markets while at the same time trying to cut down their expenses. Some of the major services an A sponsor can seek in this market include preclinical and clinical formulation services, drug delivery systems development, solid dosage form development, bioanalytical methods development, and stability engineering services as well as scale-up services. The market primarily comprises CDMOs, CROs, and formulation development companies that provide a diverse range of services due to the variation offered in the market.
• Several key drivers can be attributed to the growth of the market: the increasing rates of chronic disorders, the consistent development of biologic as well as special products, and the trend of employing more individualized medicines. Apart from that, several other reasons may force firms to seek external consulting; these include the authority pressures that compel operating units to pursue compliance with high quality standards. Regionally, North America and Europe stand out as the largest markets primarily due to their large and sophisticated pharmaceutical industries, focus on research and development, and good regulatory conditions. Yet, the Asia-Pacific new generation markets are gradually appearing as a competitive force that provides better costs and developing proficiencies. In all, the formulation development outsourcing market is one that shall continue growing for more and more firms and companies in the pharmaceutical sector aim at trying out the best, and go for the best.

Formulation Development Outsourcing Market Trend Analysis

Increasing adoption of advanced technologies and digital solutions

• Such strategic areas as artificial intelligence, machine learning, and big data have being applied to improve formulation design and process as well as to accurately predict the stabilities and efficacies. These technologies help personal, effectiveness in handling large amounts of data, sound decisions and shorter development time scales. Also, while traditional technologies in drug production have been transformed by continuous manufacturing and 3D printing in formulation are getting more popular, they open the possibility to reach higher efficacy, personalization, and a larger scale of production. It not only enhances the productivity and cost-optima of the formulation development process but also sets a good pace for a more patient-centric approach embraced by the industry lately.

Expanding field of biologics and biosimilars

• The accelerated development of these multifaceted and highly specialized drugs in the marketplace can present major formulation challenges to pharmaceutical firms mainly due to intrinsic characteristics of troublesome and sensitive biological medicine that often need enhanced systems, techniques and methods for stabilization, delivery and manufacturing. Outsourcing contractors with knowledge in formulation development of biologics can be of great help in addressing these issues, giving industry specific solutions when it comes to stabilization, solubility, and delivery options.
• In addition, with the advancement in technology and the concept of personalized medicine stands another great opportunity that is too hard to pass. Personalized medicine, in turn, concerns the development of individualized treatment strategies which necessitates fine and highly specialized formulation strategies. Outsourcing firms that place funds within themes highlighting favorable growth, like nanotechnology and advanced drug delivery system, will be able to benefit from this trend. Given their ability to provide formulation development services that are tailored for individual patients as well as using data analytics for precision medicine, these companies can expect to secure a continually increasing number of pharmaceutical and biotech clients interested in the provision of next-generation therapies. This specialization helps outsourcing partners, in turn, see themselves as indispensable stakeholders in the unfolding of the field of individualized medicine as well as to foster further growth in the formulation development outsourcing market.

Formulation Development Outsourcing Market Segment Analysis:

Formulation Development Outsourcing Market is segmented on the basis of Services type, Route of Formulation, and End-user.

By Services Type, Pre-Formulation segment is expected to dominate the market during the forecast period

• In the FDO market, Pre-Formulation will maintain its position as a primary segment in terms of demand over the forecast period. Pre-formulation services play an important role in the development process as they encompass a detailed examination of several parameters of the drug substance in its solid and liquid states, including physical, chemical, and mechanical properties. This step is the first one in the drug formulation process aimed at selecting the right formulation strategy for the drug to be stable, soluble and bioavailable.
• The Pre-Formulation segment will remain the largest segment of the PPA because of the following reasons. Firstly, the complexity of new chemical entities (NCEs) and biologics which are now developed require additional pre-formulation characterization attempts to ensure optimal understanding of their profile. Second, pharma and biotech organisations face pressure to speed up their development cycles but reduce risks which makes early outsourcing of tasks a business-critical decision to gain additional competencies and technologies in the form of effective analytics providers. Further, the rising interest in manufacturing precise and selective drugs and therapies including through post-genomic science necessitates comprehensive pre-formulation studies before designing formulations for individual requirements.
• Outsourcing of pre-formulation services is quite useful to the actualization of Cutting-Edge facilities and scientific knowledge, which indicates that fewer investments have to be made internally. It not only allows the efficient use of resources at the company’s disposal but also increases the likelihood of successful development of at least one formulation and subsequent regulatory approval. Hence, the Pre-Formulation segment shall remain dominant in the overall OSI market due to a constant need and search for effective and new solutions in creating drugs.

By Route of Formulation, Injectable segment is expected to held the largest share in 2023

• The injectable formulation segment is likely to be the largest out of all the formulation routes of formulation in the global formulation development outsourcing market. This domination comes with several factors such as; ever rising trends of chronic as well as acute diseases that call for parenteral method of delivering medication due to the effectiveness of the method. Along with solids and liquids, injectables are necessary for biologic, vaccine, and other treatments that contain molecules that cannot be consumed orally because of stability and bioavailability limitations.
• These are in part due to increasing biologics and biosimilars demand, which are mostly used in injected formulations, thus boosting this segment. A number of outsourcing partners focused on injectable formulation development will be able to provide value added services in terms of solving problems that may be associated with stability and sterility, as well as in the delivery systems which are so essential to the purpose of such formulations. Similarly, self- administration and home care signify the advantages associated with injectable systems such as pre-filled syringes and auto- injectors to increase the popularity of the injectable segment in the formulation development outsourcing market. Therefore the injectable route is still viewed as one vital sector for the pharmaceutical industries that needs to outsource formulation for development to enhance the scientific treatment fronts that meet the modern therapy needs.

Formulation Development Outsourcing Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• This segment is also expected to experience a high demand in formulation development outsourcing services based on the specific formulation route. This has been as a result of a number of factors, one of which being the continuing advancement in chronic and acute diseases necessitating parenteral administration so as to enhance the accomplishment of the treatment. The injectables play an indispensable role in treating the diseases by means of biosimilars and the vaccines or the other complex molecules that can’t be orally administered because of the considerations to stability and bioavailability.
• Moreover, the increase in the usage of biologic and biosimilar products, which are mostly in the injectable form, certainly propels this segment. Potential outsourcing partners with rendering formulation development especially for injectable formulation should possess specialist know-how that would address some issues of stability, sterility as well as delivery systems that are vital in the injectable products. The burn to self-management and home cure also complement the development of pre-filled syringes as well as auto-injectors, making injectable segment more attractive for the formulation developing outsourcing marketplace.
• As such, the injectable route present a notable interest field for pharmaceutical organizations which is keen on outsourcing formulation development to address the emerging product types in modern therapy.

Active Key Players in the Formulation Development Outsourcing Market

• SGS S.A. (Switzerland)
• Intertek Group plc (UK)
• Recipharm (Sweden)
• Lonza (Switzerland)
• Charles River Laboratories International, Inc. (USA)
• Eurofins Scientific SE (Luxembourg)
• Element (UK)
• Labcorp (USA)
• Thermo Fisher Scientific, Inc. (Patheon) (USA)
• Catalent Inc. (USA)
• Other key Players

Key Industry Developments in the Formulation Development Outsourcing Market:

• In 2021, In addition, Quotient BioSciences revealed its intention to acquire the United Kingdom-based company Arcinova. As a result of this acquisition, Quotient Bioscience has expanded its service portfolio to include drug substance development, clinical testing, and medicinal products.

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. FORMULATION DEVELOPMENT OUTSOURCING MARKET BY SERVICE TYPE (2017-2032)
   1. FORMULATION DEVELOPMENT OUTSOURCING MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. PRE-FORMULATION
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. FORMULATION DEVELOPMENT
7. FORMULATION DEVELOPMENT OUTSOURCING MARKET BY ROUTE OF FORMULATION (2017-2032)
   1. FORMULATION DEVELOPMENT OUTSOURCING MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. ORAL
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. INJECTABLE
   5. OTHERS
8. FORMULATION DEVELOPMENT OUTSOURCING MARKET BY END USER (2017-2032)
   1. FORMULATION DEVELOPMENT OUTSOURCING MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. PHARMACEUTICAL INDUSTRIES
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. RESEARCH AND ACADEMIC INSTITUTES
9. COMPANY PROFILES AND COMPETITIVE ANALYSIS
   1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. Formulation Development Outsourcing Market Share By Manufacturer (2023)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
   2. COMPANYA
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
   3. SGS S.A. (SWITZERLAND)
   4. INTERTEK GROUP PLC (UK)
   5. RECIPHARM (SWEDEN)
   6. LONZA (SWITZERLAND)
   7. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (USA)
   8. EUROFINS SCIENTIFIC SE (LUXEMBOURG)
   9. ELEMENT (UK)
   10. LABCORP (USA)
   11. THERMO FISHER SCIENTIFIC, INC. (PATHEON) (USA)
   12. CATALENT INC. (USA)
10. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Service Type
       4. Historic And Forecasted Market Size By Route of Formulation
       5. Historic And Forecasted Market Size By End User
       6. Historic And Forecasted Market Size By Country
          1. USA
          2. Canada
          3. Mexico
    3. EASTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Russia
          2. Bulgaria
          3. The Czech Republic
          4. Hungary
          5. Poland
          6. Romania
          7. Rest Of Eastern Europe
    4. WESTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Germany
          2. United Kingdom
          3. France
          4. The Netherlands
          5. Italy
          6. Spain
          7. Rest Of Western Europe
    5. ASIA PACIFIC
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. China
          2. India
          3. Japan
          4. South Korea
          5. Malaysia
          6. Thailand
          7. Vietnam
          8. The Philippines
          9. Australia
          10. New-Zealand
          11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Turkey
          2. Bahrain
          3. Kuwait
          4. Saudi Arabia
          5. Qatar
          6. UAE
          7. Israel
          8. South Africa
    7. SOUTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
11. INVESTMENT ANALYSIS
12. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. FORMULATION DEVELOPMENT OUTSOURCING MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. FORMULATION DEVELOPMENT OUTSOURCING MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. FORMULATION DEVELOPMENT OUTSOURCING MARKET COMPETITIVE RIVALRY
TABLE 005. FORMULATION DEVELOPMENT OUTSOURCING MARKET THREAT OF NEW ENTRANTS
TABLE 006. FORMULATION DEVELOPMENT OUTSOURCING MARKET THREAT OF SUBSTITUTES
TABLE 007. FORMULATION DEVELOPMENT OUTSOURCING MARKET BY SERVICE
TABLE 008. PRE-FORMULATION SERVICES MARKET OVERVIEW (2016-2028)
TABLE 009. FORMULATION OPTIMIZATION MARKET OVERVIEW (2016-2028)
TABLE 010. FORMULATION DEVELOPMENT OUTSOURCING MARKET BY APPLICATION
TABLE 011. ONCOLOGY MARKET OVERVIEW (2016-2028)
TABLE 012. GENETIC DISORDERS MARKET OVERVIEW (2016-2028)
TABLE 013. NEUROLOGY MARKET OVERVIEW (2016-2028)
TABLE 014. INFECTIOUS DISEASES MARKET OVERVIEW (2016-2028)
TABLE 015. RESPIRATORY MARKET OVERVIEW (2016-2028)
TABLE 016. CARDIOVASCULAR MARKET OVERVIEW (2016-2028)
TABLE 017. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 018. FORMULATION DEVELOPMENT OUTSOURCING MARKET BY DOSAGE FORM
TABLE 019. INJECTABLE MARKET OVERVIEW (2016-2028)
TABLE 020. ORAL MARKET OVERVIEW (2016-2028)
TABLE 021. TOPICAL MARKET OVERVIEW (2016-2028)
TABLE 022. OTHER MARKET OVERVIEW (2016-2028)
TABLE 023. NORTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICE (2016-2028)
TABLE 024. NORTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION (2016-2028)
TABLE 025. NORTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM (2016-2028)
TABLE 026. N FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY (2016-2028)
TABLE 027. EUROPE FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICE (2016-2028)
TABLE 028. EUROPE FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION (2016-2028)
TABLE 029. EUROPE FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM (2016-2028)
TABLE 030. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY (2016-2028)
TABLE 031. ASIA PACIFIC FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICE (2016-2028)
TABLE 032. ASIA PACIFIC FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION (2016-2028)
TABLE 033. ASIA PACIFIC FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM (2016-2028)
TABLE 034. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY (2016-2028)
TABLE 035. MIDDLE EAST & AFRICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICE (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION (2016-2028)
TABLE 037. MIDDLE EAST & AFRICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM (2016-2028)
TABLE 038. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY (2016-2028)
TABLE 039. SOUTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICE (2016-2028)
TABLE 040. SOUTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION (2016-2028)
TABLE 041. SOUTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM (2016-2028)
TABLE 042. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY (2016-2028)
TABLE 043. CHARLES RIVER LABORATORIES INTERNATIONAL INC.: SNAPSHOT
TABLE 044. CHARLES RIVER LABORATORIES INTERNATIONAL INC.: BUSINESS PERFORMANCE
TABLE 045. CHARLES RIVER LABORATORIES INTERNATIONAL INC.: PRODUCT PORTFOLIO
TABLE 046. CHARLES RIVER LABORATORIES INTERNATIONAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. AIZANT DRUG RESEARCH SOLUTIONS PVT LIMITED: SNAPSHOT
TABLE 047. AIZANT DRUG RESEARCH SOLUTIONS PVT LIMITED: BUSINESS PERFORMANCE
TABLE 048. AIZANT DRUG RESEARCH SOLUTIONS PVT LIMITED: PRODUCT PORTFOLIO
TABLE 049. AIZANT DRUG RESEARCH SOLUTIONS PVT LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. CATALENT INC.: SNAPSHOT
TABLE 050. CATALENT INC.: BUSINESS PERFORMANCE
TABLE 051. CATALENT INC.: PRODUCT PORTFOLIO
TABLE 052. CATALENT INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. LABORATORY CORPORATION OF AMERICA HOLDINGS: SNAPSHOT
TABLE 053. LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS PERFORMANCE
TABLE 054. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 055. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. BIOCON LIMITED (SYNGENE INTERNATIONAL): SNAPSHOT
TABLE 056. BIOCON LIMITED (SYNGENE INTERNATIONAL): BUSINESS PERFORMANCE
TABLE 057. BIOCON LIMITED (SYNGENE INTERNATIONAL): PRODUCT PORTFOLIO
TABLE 058. BIOCON LIMITED (SYNGENE INTERNATIONAL): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. IRISYS LLC: SNAPSHOT
TABLE 059. IRISYS LLC: BUSINESS PERFORMANCE
TABLE 060. IRISYS LLC: PRODUCT PORTFOLIO
TABLE 061. IRISYS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. INTERTEK GROUP PLC: SNAPSHOT
TABLE 062. INTERTEK GROUP PLC: BUSINESS PERFORMANCE
TABLE 063. INTERTEK GROUP PLC: PRODUCT PORTFOLIO
TABLE 064. INTERTEK GROUP PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. PIRAMAL ENTERPRISES LTD: SNAPSHOT
TABLE 065. PIRAMAL ENTERPRISES LTD: BUSINESS PERFORMANCE
TABLE 066. PIRAMAL ENTERPRISES LTD: PRODUCT PORTFOLIO
TABLE 067. PIRAMAL ENTERPRISES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. QUOTIENT SCIENCES: SNAPSHOT
TABLE 068. QUOTIENT SCIENCES: BUSINESS PERFORMANCE
TABLE 069. QUOTIENT SCIENCES: PRODUCT PORTFOLIO
TABLE 070. QUOTIENT SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. THERMO FISHER SCIENTIFIC INC. (PATHEON): SNAPSHOT
TABLE 071. THERMO FISHER SCIENTIFIC INC. (PATHEON): BUSINESS PERFORMANCE
TABLE 072. THERMO FISHER SCIENTIFIC INC. (PATHEON): PRODUCT PORTFOLIO
TABLE 073. THERMO FISHER SCIENTIFIC INC. (PATHEON): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. EMERGENT BIOSOLUTIONS INC.: SNAPSHOT
TABLE 074. EMERGENT BIOSOLUTIONS INC.: BUSINESS PERFORMANCE
TABLE 075. EMERGENT BIOSOLUTIONS INC.: PRODUCT PORTFOLIO
TABLE 076. EMERGENT BIOSOLUTIONS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. LONZA GROUP AG: SNAPSHOT
TABLE 077. LONZA GROUP AG: BUSINESS PERFORMANCE
TABLE 078. LONZA GROUP AG: PRODUCT PORTFOLIO
TABLE 079. LONZA GROUP AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. AURIGENE PHARMACEUTICAL SERVICES LTD: SNAPSHOT
TABLE 080. AURIGENE PHARMACEUTICAL SERVICES LTD: BUSINESS PERFORMANCE
TABLE 081. AURIGENE PHARMACEUTICAL SERVICES LTD: PRODUCT PORTFOLIO
TABLE 082. AURIGENE PHARMACEUTICAL SERVICES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. PCI PHARMA SERVICES: SNAPSHOT
TABLE 083. PCI PHARMA SERVICES: BUSINESS PERFORMANCE
TABLE 084. PCI PHARMA SERVICES: PRODUCT PORTFOLIO
TABLE 085. PCI PHARMA SERVICES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 085. HERMES PHARMA: SNAPSHOT
TABLE 086. HERMES PHARMA: BUSINESS PERFORMANCE
TABLE 087. HERMES PHARMA: PRODUCT PORTFOLIO
TABLE 088. HERMES PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 088. PYRAMID LABORATORIES INC: SNAPSHOT
TABLE 089. PYRAMID LABORATORIES INC: BUSINESS PERFORMANCE
TABLE 090. PYRAMID LABORATORIES INC: PRODUCT PORTFOLIO
TABLE 091. PYRAMID LABORATORIES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 091. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 092. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 093. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 094. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY SERVICE
FIGURE 012. PRE-FORMULATION SERVICES MARKET OVERVIEW (2016-2028)
FIGURE 013. FORMULATION OPTIMIZATION MARKET OVERVIEW (2016-2028)
FIGURE 014. FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY APPLICATION
FIGURE 015. ONCOLOGY MARKET OVERVIEW (2016-2028)
FIGURE 016. GENETIC DISORDERS MARKET OVERVIEW (2016-2028)
FIGURE 017. NEUROLOGY MARKET OVERVIEW (2016-2028)
FIGURE 018. INFECTIOUS DISEASES MARKET OVERVIEW (2016-2028)
FIGURE 019. RESPIRATORY MARKET OVERVIEW (2016-2028)
FIGURE 020. CARDIOVASCULAR MARKET OVERVIEW (2016-2028)
FIGURE 021. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 022. FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY DOSAGE FORM
FIGURE 023. INJECTABLE MARKET OVERVIEW (2016-2028)
FIGURE 024. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 025. TOPICAL MARKET OVERVIEW (2016-2028)
FIGURE 026. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 027. NORTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. EUROPE FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. ASIA PACIFIC FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. MIDDLE EAST & AFRICA FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. SOUTH AMERICA FORMULATION DEVELOPMENT OUTSOURCING MARKET OVERVIEW BY COUNTRY (2016-2028)